Daily News Podcast

Rivaroxaban data abound at ESC 2018

Publish date: August 28, 2018

 

New results from the ASCEND trial show that neither aspirin nor fish oil provides any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

Medicare Advantage pushback
MDedge Dermatology
Psoriasis registry study provides more data on infliximab’s infection risk
MDedge Dermatology
FDA approves first EpiPen generic
MDedge Dermatology
Cardiovascular risk management supported for type 2 diabetes
MDedge Dermatology
Sleepio app tied to reducing insomnia, depression
MDedge Dermatology
Telangiectatic Patch on the Neck
MDedge Dermatology
5 digital HIPAA myths
MDedge Dermatology
Screen for cervical cancer based on age, risk
MDedge Dermatology
Is it time for PCPs to take over chronic HCV?
MDedge Dermatology
Lorcaserin shows cardiovascular safety
MDedge Dermatology